XENE Xenon Pharmaceuticals
- 40.790
- +0.700+1.75%
- 40.790
- 0.0000.00%
Xenon Pharmaceuticals News
Xenon Pharmaceuticals | S-3ASR: Automatic shelf registration statement of securities of well-known seasoned issuers
Xenon Pharmaceuticals | 10-Q: Q2 2024 Earnings Report
Xenon Pharmaceuticals | 8-K: Current report
Xenon Pharmaceuticals | 144: Notice of proposed sale of securities pursuant to Rule 144
Xenon Pharmaceuticals | 144: Notice of proposed sale of securities pursuant to Rule 144
Xenon Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director PATOU GARY
Xenon Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Machado Patrick
Xenon Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Gover Justin D.
Xenon Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director GAROFALO ELIZABETH A.
Xenon Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director GANNON STEVEN
Xenon Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Cannon Gillian
Xenon Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Svoronos Dawn
Xenon Pharmaceuticals | 144: Notice of proposed sale of securities pursuant to Rule 144
Xenon Pharmaceuticals | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
Xenon Pharmaceuticals | 8-K: Current report
Xenon Pharmaceuticals | 10-Q: Q1 2024 Earnings Report
Xenon Pharmaceuticals | 8-K: Xenon Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update
Xenon Pharmaceuticals | DEF 14A: Definitive information statements
Xenon Pharmaceuticals | ARS: Annual Report to Security Holders
Xenon Pharmaceuticals | 8-K: Current report
Analysis
Price Target
No Data
No Data